BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Atigotatug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Atigotatug\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06646276-11178@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Atigotatug: Phase 3 readout est. (NCT06646276)
DESCRIPTION:Atigotatug\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study 
 to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fi
 xed Dose Combination) in Combination With Carboplatin Plus Etoposide to Th
 at of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy i
 n Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).\nEstim
 ated primary completion: 17 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atigotatug#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06646276
URL:https://assetmemo.bio/drug/atigotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
